ArcticZymes Technologies ASA

AZT

NO0010014632

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-06-03 EDT			5-day change	1st Jan Change
26.15 ^NOK	+2.15%		+0.77%	-37.74%

05-13	ArcticZymes Technologies ASA Announces Board Resignations	CI
05-08	ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Biotec Pharmacon Asa Announces Board Changes

November 22, 2019 at 01:57 pm

Biotec Pharmacon ASA announced Board members Arne Reinemo and Inger Rydin informed that they resign from the Board with immediate effect.

Latest news about ArcticZymes Technologies ASA

ArcticZymes Technologies ASA Announces Board Resignations	05-13	CI
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Transcript : ArcticZymes Technologies ASA, Q1 2024 Earnings Call, May 08, 2024	05-08
Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project	04-09	MT
ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology	04-09	CI
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member	04-02	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-01	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Full Year Ended December 31, 2023	02-01	CI
Transcript : ArcticZymes Technologies ASA, Q4 2023 Earnings Call, Feb 01, 2024	02-01
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq	01-30	CI
Norway’s ArcticZymes Technologies Manufactures GMP-grade Enzyme	01-30	MT
ArcticZymes Technologies ASA Launches T7 RNA Polymerase	12-21	CI
ArcticZymes Technologies ASA Enters into an Agreement with Biomatter	12-19	CI
ArcticZymes Technologies ASA Announces Partnership with Biomatter	12-19	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Transcript : ArcticZymes Technologies ASA, Q3 2023 Earnings Call, Nov 02, 2023	11-02
ArcticZymes Technologies' Wins US FDA's Filing Type 2 Status for Enzyme	23-09-21	MT
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA	23-09-21	CI
ArcticZymes Technologies ASA(OB:AZT) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : ArcticZymes Technologies ASA, Q2 2023 Earnings Call, Aug 17, 2023	23-08-17
ArcticZymes Technologies ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
ArcticZymes Technologies ASA Launches Taq?? DNA Polymerase	23-08-09	CI
ArcticZymes Technologies Appoints New CEO	23-07-17	MT
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023	23-07-17	CI
ArcticZymes Technologies Files DMF for SAN HQ GMP	23-06-29	CI

Chart ArcticZymes Technologies ASA

Duration

Period

More charts

Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Companyâs enzymes include cold activeness and salt tolerance. The Companyâs divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ArcticZymes Technologies ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.15 NOK

Average target price

27.5 NOK

Spread / Average Target

+5.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCTICZYMES TECHNOLOGIES ASA	-37.74%	124M
MODERNA, INC.	+48.64%	54.63B
IQVIA HOLDINGS INC.	-6.44%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.40%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.64%	12.21B
BIO-TECHNE CORPORATION	+0.96%	12.16B
MEDPACE HOLDINGS, INC.	+27.04%	11.94B

Other Biotechnology & Medical Research

ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Biotec Pharmacon Asa Announces Board Changes

Latest news about ArcticZymes Technologies ASA

Chart ArcticZymes Technologies ASA

Company Profile

Income Statement Evolution

Ratings for ArcticZymes Technologies ASA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research